This is a preview of subscription content, log in via an institution to check access.
Reference
Wang H, et al. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open : 12 Feb 2020. Available from: URL: http://dx.doi.org/10.1136/bmjopen-2019-030738
Rights and permissions
About this article
Cite this article
Cetuximab + chemotherapy in metastatic CRC: not cost effective in China. PharmacoEcon Outcomes News 847, 5 (2020). https://doi.org/10.1007/s40274-020-6581-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6581-3